{
Amgen Inc.

Companies

}
Symbol AMGN
Name Amgen Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country United States
State CA
City Thousand Oaks
Zipcode 91320-1799
Website http://www.amgen.com
Track all markets on TradingView
Novo obesity data boosts outlook for Eli Lilly and Amgen stocks
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
Yahoo Finance
Amgen Inc. Novo Nordisk A/S Eli Lilly and Company DNK Trung Huynh Show more
Healthcare, Market Report
13:30 21.12.2024
Eli Lilly and Amgen benefit from Novo Nordisk's disappointing obesity data
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
Yahoo Finance
Novo Nordisk A/S Amgen Inc. Eli Lilly and Company DNK Trung Huynh Show more
Healthcare, Market Report
13:30 21.12.2024
Novartis to close MorphoSys sites and lay off 330 employees
Novartis is closing MorphoSys sites in Munich and Boston, resulting in approximately 330 layoffs, as part of its integration strategy following the €2.7 billion acquisition earlier this year. The decision aligns with a focus on prioritizing R&D programs, particularly the delayed approval pathway for the oncology candidate pelabresib. This trend of post-acquisition job cuts has been observed across several major pharma companies in recent years.
Fierce Pharma
Euro Sanofi GSK plc Gilead Sciences, Inc. Incyte Corp Novartis AG Immunomedics Inc. Horizon Therapeutics Public Lim Bellus Health Inc. Merck & Co., Inc. Bristol-Myers Squibb Co Amgen Inc. MorphoSys AG USA DEU CHE Vas Narasimhan Show more
Finance & Economy, News Article
15:47 19.12.2024
novartis and bioage partner to tackle age-related diseases in major deal
BioAge Labs has entered a multi-year partnership with Novartis to tackle age-related diseases, potentially worth up to $550 million. The collaboration will leverage BioAge's human longevity datasets and Novartis's expertise in exercise biology to discover new therapeutic targets and explore the biological mechanisms of aging. This agreement follows BioAge's recent IPO and the discontinuation of a phase 2 obesity trial due to safety concerns.
Fierce Biotech
United States Dollar Novartis AG Amgen Inc. BioAge Labs, Inc. Eli Lilly and Company USA CHE Lai Peng Leong Michaela Kneissel Kristen Fortney Show more
Healthcare, Press Release
16:44 18.12.2024
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Fierce Pharma
United States Dollar Bayer AG Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG Amgen Inc. USA George Yancopoulos Show more
Healthcare, Market Report
14:20 18.12.2024
Amgen Inc. Maintains Neutral Rating Amid Strong Drug Sales Performance
Amgen Inc., a leading biotechnology company, generates 94.2% of its net sales from drug sales, focusing on treatments for cancer, metabolic disorders, bone diseases, kidney failure, and hemophilia. The company derives 5.8% of its revenue from licensing income, with the United States accounting for 70.3% of total net sales. UBS has reiterated its neutral rating on the company.
MarketScreener
United States Dollar Amgen Inc. USA
Healthcare, Market Report
16:03 17.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024
OptumRx favors Amgen's Amjevita over Sandoz and Boehringer biosimilars
OptumRx, the pharmacy benefit manager for UnitedHealth Group, will exclude Sandoz's Hyrimoz and Boehringer Ingelheim's Cyltezo from its 2025 US commercial formularies, favoring Amgen's Amjevita instead. Starting January 1, 2025, Humira will be classified as a tier three product, while Amjevita will be tier two.
Insights
Sandoz Group AG UnitedHealth Group Inc Boehringer Ingelheim KG Amgen Inc. USA Show more
Healthcare, Market Report
17:27 13.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
Fierce Biotech
United States Dollar Hoffmann-La Roche AG Gilead Sciences, Inc. Bayer AG Immunomedics Inc. Genentech Amgen Inc. Sanofi USA FRA John S. Reed Houman Ashrafian Daniel O'Day Merdad Parsey Dietmar Berger Show more
Healthcare, News Article
11:20 13.12.2024
BioAge Labs Halts Obesity Drug Study Shares Plummet Due to Safety Concerns
BioAge Labs has halted its mid-stage study of the obesity drug azelaprag due to safety concerns after participants showed elevated liver enzymes, leading to a 75% drop in share price. The company plans to provide an update on azelaprag's development in early 2025, while also pursuing another program targeting central nervous system disorders.
BioPharma Dive
United States Dollar BioAge Labs, Inc. Novo Nordisk A/S Eli Lilly and Company Amgen Inc. USA Kristen Fortney Show more
Healthcare, News Article
01:00 07.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Emerging Startups Cryptocurrency Regulations Inflation Rates & CPI Data SEC & Financial Compliance Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN CHN IND SGP DNK CAN NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Ripples USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.